ALKS Earnings Date: Nov 3, 2026 (Estimated) — Alkermes plc
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
Updated
When is ALKS's next earnings date?
Alkermes plc (ALKS) is expected to report earnings on Tuesday, November 3, 2026; the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.08 on revenue of $463.5M.
How did ALKS do in its last earnings report?
In its most recent report on Jul 28, 2026 (Q2 2026), Alkermes plc posted EPS of $0.00 versus the $0.14 estimate, a miss of 100.0%. Revenue was $496.0M against a $456.9M estimate. The stock's 1-day post-earnings move was -4.2%.
How much does ALKS stock move after earnings?
ALKS beat EPS estimates in 4 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 4.9% (up or down) in the day after earnings.
About Alkermes plc
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-28 | Q2 2026 | 0.14 | 0.00 | -100.00% | $496.0M | ❌ Miss | -4.23% | -6.07% | -6.68% |
| 2026-05-05 | Q1 2026 | -0.15 | -0.40 | -166.67% | $392.9M | ❌ Miss | +6.09% | +3.80% | +25.14% |
| 2026-02-25 | Q4 2025 | 0.38 | 0.29 | -23.68% | $384.5M | ❌ Miss | -7.04% | -12.55% | -12.04% |
| 2025-10-28 | Q3 2025 | 0.37 | 0.49 | +32.43% | $394.2M | ✅ Beat | +4.31% | +1.51% | -2.46% |
| 2025-07-29 | Q2 2025 | 0.34 | 0.52 | +52.94% | $390.7M | ✅ Beat | +3.25% | +1.85% | +10.82% |
| 2025-02-12 | Q4 2024 | 0.76 | 1.04 | +36.84% | $430.0M | ✅ Beat | +4.82% | +12.14% | +5.19% |
| 2024-10-24 | Q3 2024 | 0.74 | 0.72 | -2.70% | $378.1M | ❌ Miss | -3.59% | -5.53% | -0.54% |
| 2024-07-24 | Q2 2024 | 0.70 | 0.72 | +2.86% | $399.1M | ✅ Beat | +6.04% | +10.52% | +13.04% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $726.9M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Product | 56.6% | $411.7M | +34.0% | $307.7M | $244.5M | $307.2M | $317.4M |
| Vivitrol | 17.1% | $124.5M | +2.3% | $134.1M | — | $121.7M | $121.1M |
| Aristada And Aristada Initio | 13.3% | $96.7M | -4.5% | $96.6M | — | $101.3M | $98.0M |
| L Y B A L V I | 12.9% | $94.0M | +11.5% | $77.0M | — | $84.3M | $98.2M |
By region
FY2025 · $1.48B total · annual
| Segment | Share | Revenue | YoY | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 93.0% | $1.37B | -2.7% | $966.9M | $839.0M | $984.2M | $932.0M |
| Foreign Country Excluding Specified Country | 6.9% | $102.4M | -30.0% | $200.8M | $196.5M | $187.3M | $178.0M |
| IRELAND | 0.1% | $754K | -41.7% | $3.2M | $3.2M | $2.2M | $1.8M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.